Anodyne

Selegiline
Selegiline
Molecular structure via molpic based on CDK
[]
Conformer structure via JSmol
Physical properties
[]
187.28 g/mol [1]
Melting point141-142 °C [1]
2.8 [1]
Structural Identifiers
[]
C13H17[1]
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine [1]
C[C@H](CC1=CC=CC=C1)N(C)CC#C [1]
InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1 [1]
InChIKeyMEZLKOACVSPNER-GFCCVEGCSA-N [1]
Dosing
[]
Elimination half-lifeOral:• Selegiline (single): 1.2 – 3.5 h• Selegiline (multi): 7.7 – 9.7 h• Desmethylselegiline (single): 2.2 – 3.8 h• Desmethylselegiline (multi): 9.5 h• Levomethamphetamine: 14 – 21 h• Levoamphetamine: 16 – 18 hOrally disintegrating tablet:• Selegiline (single): 1.3 h• Selegiline (multi): 10 hPatch:• Selegiline: 20 h[4]
Duration of actionProlonged use:Oral: 2 – 3 days (Parkinson's disease relief)

Selegiline

Selegiline (also known as (-)-selegiline, Selegilina, selgene, Selegilinum, (-)-Deprenil, Zalapar, Otrasel, Selegene, (R)-(-)-Selegiline or l-E 250) is a monoamine oxidase inhibitor substance of the amphetamine class.

Chemistry

Salts []

Selegiline is typically found in the form of its hydrochloride salt.

 []

Selegiline is a absolute mixture

Experience reports []

Legal status []

  • Australia: Selegiline is a S4 substance.
  • Brazil: Selegiline is a C1 substance.[3]
  • Canada: Selegiline is a prescription only substance.
  • United Kingdom: Selegiline is a prescription only substance.
  • United States: Selegiline is a prescription only substance.

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 26757, Selegiline. Accessed June 26, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/26757

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Selegiline. UNII: 2K1V7GP655. Global Substance Registration System. Accessed June 26, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2K1V7GP655

  3. Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 26, 2025. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992

  4. EMSAM® (Selegiline Transdermal System) Label. Food and Drug Administration. July 1, 2017. Accessed June 26, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021336s014lbl.pdf